Unified – Type of Agreement

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

10 months ago talkbio0Tagged AMT-130, cUHDRS, Disease Progression, gene therapy, Huntington 's disease, Huntington 's Disease Rating Scale, Identifier, neurofilament protein L, NfL, Phase I/II trials, Regenerative Medicine, RMAT, Unified - Type of Agreement, UniQure

uniQure, Huntington’s disease, AMT-130, gene therapy, Phase I/II trials, disease progression, neurofilament light protein (NfL), Unified Huntington’s Disease Rating Scale (cUHDRS), Regenerative Medicine Advanced Therapy (RMAT) designation

UniQure Wins First FDA RMAT in Huntington’s Disease After Strong Phase I/II Data

10 months ago talkbio0Tagged AMT-130, Clinical Trials, Composite, cUHDRS, Disease Progression, gene therapy, Huntington 's disease, Huntington 's Disease Rating Scale, Identifier, NEFL gene, Neurodegenerative Disorders, NfL, Phase, RMAT, Unified - Type of Agreement, UniQure, United States Food and Drug Administration

UniQure, Huntington’s disease, gene therapy, AMT-130, FDA, RMAT designation, Phase I/II clinical trials, neurodegenerative disorder, neurofilament light (NfL), disease progression, composite Unified Huntington’s Disease Rating Scale (cUHDRS).

Annovis Bio Reports Promising Phase III Study Results for Buntanetap in Parkinson’s Disease Treatment

10 months ago talkbio0Tagged Annovis, Bio, buntanetap, Cognition, MDS-UPDRS, Motor function (observable entity), Neurodegenerative Disorders, Parkinson 's disease, Parkinson 's Disease Rating Scale, Phase 3 Clinical Trials, Unified - Type of Agreement

Annovis Bio, Buntanetap, Parkinson’s Disease, Phase III Study, Neurodegenerative Disorders, Cognitive Function, Motor Functions, Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)